The transaction details are sourced from an SEC EDGAR filing published on May 21, 2025. The specific form type is not disclosed in the available information. The deal is currently in pending-regulatory status, indicating that approvals or clearances are still awaited before the transaction can move forward to closing.
Goldman Sachs is serving as the exclusive financial advisor to BeautyHealth on this transaction, taking the lead role in that capacity. Latham & Watkins LLP is serving as transaction counsel to BeautyHealth, providing legal advisory services to the issuer side of the deal.
No information has been disclosed regarding the specific structure or terms of the convertible debt exchange or refinancing. This includes whether the transaction involves an exchange of existing convertible securities for new ones, a refinancing of current convertible debt into a new instrument, or another form of convertible restructuring. The consideration structure, pricing, conversion terms, maturity date, coupon or dividend rate, or any other specific financial terms are not provided in the available source material. Additionally, there is no expected closing date disclosed, no information on the size of the existing convertible debt being exchanged or refinanced, and no details regarding whether this is a registered offering, private placement, or other regulatory structure. The reason for the exchange or refinancing and any details about the financial condition or strategic context driving the transaction are likewise not disclosed.